Korean J Hematol.  2006 Dec;41(4):282-288. 10.5045/kjh.2006.41.4.282.

Prospective Randomized Comparative Observations of Infectious Complications with or without Antimicrobial Prophylaxis, during Autologous Stem Cell Transplantation

• Koo DH
• Ko OB
• Kim S
• Lee DH
• Kim SW
• Suh C

• KMID: 2305215
• DOI: http://doi.org/10.5045/kjh.2006.41.4.282

Abstract

BACKGROUND: A prospective randomized comparative observation was performed to assess the benefit of prophylactic antimicrobials in autologous stem cell transplantation (ASCT).
METHODS
Forty consecutive patients, with multiple myelomas (MM, 28 patients) or a non-Hodgkin's lymphoma (NHL, 12 patients), were stratified by disease and randomly allocated to receive (prophylaxis group, 21 patients) or not receive (control group, 19 patients) prophylactic antimicrobials. The prophylactic antimicrobials consisted of ciprofloxacin (500mg twice daily p.o.), fluconazole (100mg twice daily p.o.) and acyclovir (400mg every 8 h p.o.), starting 1 day before high-dose chemotherapy (high-dose melphalan for MM and BEAM for NHL), and continuing until neutrophil engraftment or the occurrence of infection.
RESULTS
At least one episode of fever occurred in 15 of the 19 (79%) patients in the control group, compared with 12 of the 21 (57%) in the prophylaxis group (P=NS). Microbiologically or clinically documented infections occurred in 4 patients (21%) in the control group, but none occurred in the prophylaxis group (P=NS). The documented infections in the control group included 3 staphylococcal bacteremias and 1 herpes skin infection. No deaths, invasive fungal infections or serious adverse events occurred in either group. The median duration of fever (9 days in the control group and 11 days in the prophylaxis group), therapeutic antimicrobial therapy (9 days in the control group and 11 days in the prophylaxis group) and hospital stay after ASCT (19 days in both groups) did not differ between the groups.
CONCLUSION
This small-sized prospective randomized comparative observation showed no beneficial effects of antimicrobial prophylaxis in ASCT.

Keyword

Autologous stem cell transplantation; Infectious complications; Antimicrobial prophylaxis

MeSH Terms

Acyclovir
Bacteremia
Ciprofloxacin
Drug Therapy
Fever
Fluconazole
Humans
Length of Stay
Lymphoma, Non-Hodgkin
Melphalan
Multiple Myeloma
Neutrophils
Prospective Studies*
Skin
Stem Cell Transplantation*
Stem Cells*
Acyclovir
Ciprofloxacin
Fluconazole
Melphalan

Reference

1). Salazar R., Sola C., Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999. 23:27–33.

2). Solano C., Gutierrez A., Martinez F, et al. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam. Bone Marrow Transplant. 2005. 36:59–65.

3). Reich G., Mapara MY., Reichardt P., Dorken B., Mas-chmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001. 27:525–9.

4). Sepkowitz KA. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant. 2002. 29:367–71.

5). Schmitz N., Linch DC., Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996. 347:353–7.

6). Hartmann O., Le Corroller AG., Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. Arandomized controlled trial. Ann Intern Med. 1997. 126:600–7.

7). Kruger WH., Hornung RJ., Hertenstein B, et al. Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European Group for Blood and Marrow Transplantation. J Hematother Stem Cell Res. 2001. 10:895–903.

8). Cruciani M., Rampazzo R., Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996. 23:795–805.

9). Tunkel AR., Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002. 34:1524–9.

10). Yeh SP., Hsueh EJ., Yu MS., Wu H., Wang YC. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. Bone Marrow Transplant. 1999. 24:1207–11.

11). Yeh SP., Chiu CF., Lo WJ, et al. Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis. Ann Hematol. 2003. 82:24–9.

12). Lee JL., Kim SB., Lee GW, et al. The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Yonsei Med J. 2003. 44:800–10.

13). Caballero MD., Rubio V., Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997. 20:451–8.

14). Hughes WT., Armstrong D., Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002. 34:730–51.

15). Simon R., Wittes RE., Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985. 69:1375–81.

16). Beyer J., Schwella N., Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995. 13:1328–35.

17). Kolbe K., Domkin D., Derigs HG., Bhakdi S., Huber C., Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997. 19:143–7.

18). Reuter S., Kern WV., Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005. 40:1087–93.

19). Cullen M., Steven N., Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005. 353:988–98.

20). Bucaneve G., Micozzi A., Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005. 353:977–87.

21). Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med. 2005. 353:1052–4.